Nitin Trivedi, MD
Endocrinology, Diabetes & Metabolism · Worcester, MANPI 1770543977
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $346,370 of the $402,513 with a category attached, or 86.1%. Lilly USA, LLC accounts for 60.5% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $109,824 and has fallen 93.2% since, to $7,516 in 2025. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $642.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$244K
- Novo Nordisk$45K
- Boehringer Ingelheim$30K
- AstraZeneca$30K
- Sanofi-aventis U.S. LLC$22K
- Johnson & Johnson$11K
- plus $21K from 26 others
What the payments were for
- Consulting fees$15,7634%
- Speaking & faculty fees$346,37086%
- Travel & lodging$28,2177%
- Food & beverage$10,7823%
- Education$1,3810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 331 | $243,529 |
| Novo Nordisk | 72 | $44,509 |
| Boehringer Ingelheim | 48 | $30,225 |
| AstraZeneca(2 entities) | 46 | $30,223 |
| Sanofi-aventis U.S. LLC | 33 | $21,805 |
| Johnson & Johnson | 22 | $11,451 |
| Dexcom, Inc. | 14 | $11,181 |
| Corcept Therapeutics | 10 | $3,783 |
| Zealand Pharma US, Inc. | 2 | $1,600 |
| Medtronic(2 entities) | 8 | $1,416 |
| Eli Lilly | 1 | $1,050 |
| Abbott | 6 | $375 |
| Amgen | 4 | $265 |
| Kyowa Kirin, Inc. | 2 | $151 |
| Ascensia Diabetes Care US Inc. | 1 | $120 |
| Cequr Corporation | 1 | $113 |
| Bigfoot Biomedical Inc | 1 | $111 |
| Ascendis Pharma Endocrinology Inc | 2 | $88 |
| Recordati_rare_diseases_inc. | 3 | $77 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| Tandem Diabetes Care, Inc. | 2 | $63 |
| Novartis | 3 | $63 |
| Bayer | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Radius Health, Inc. | 1 | $28 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Sequel Med Tech, LLC | 1 | $21 |
| Mannkind Corporation | 1 | $21 |
| IBSA Pharma Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Insulet Corporation | 1 | $18 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$98,833
- JARDIANCE$65,254
- MOUNJARO$63,321
- FARXIGA$29,392
- Ozempic$18,959
- SOLIQUA 100/33$11,214
- INVOKANA$11,134
- DEXCOM G7 GSS (161)$10,860
- RYBELSUS$9,749
- Tresiba$8,313
- TOUJEO$7,849
- DEXCOM STELO GLUCOSE BIOSENSOR$6,647
- Victoza$5,090
- Korlym$3,630
- ZEGALOGUE$1,600
- Minimed 670G System$1,250
- FreeStyle Lite system$200
- CRYSVITA$128
- DEXCOM CGM$119
- CeQur Simplicity$113
How this compares
$402,513 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 446 | $563,097 |
| OzempicSemaglutide | 474 | $552,914 |
| MounjaroTirzepatide | 288 | $356,472 |
| JardianceEmpagliflozin | 328 | $323,127 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 68 | $132,690 |
| Tresiba Flextouch U-200Insulin Degludec | 100 | $109,134 |
| Tresiba Flextouch U-100Insulin Degludec | 187 | $103,367 |
| FarxigaDapagliflozin Propanediol | 99 | $81,324 |
| TymlosAbaloparatide | 26 | $67,343 |
| JanuviaSitagliptin Phosphate | 69 | $65,389 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $64,819 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 74 | $63,328 |
| ProliaDenosumab | 37 | $63,251 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $45,660 |
| RybelsusSemaglutide | 32 | $43,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $243,529 | $940,984812 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $44,509 | $631,667575 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $30,225 | $379,686384 claims |
| AstraZenecaFarxiga | $30,223 | $81,32499 claims |
| Radius Health, Inc.Tymlos | $28 | $67,34326 claims |
| AmgenProlia | $265 | $63,25137 claims |
| AbbVieSynthroid | $16 | $10,044103 claims |
| Sanofi-aventis U.S. LLCLantus | $21,805 | $6,37730 claims |
| IBSA Pharma Inc.Tirosint | $20 | $4,38322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Worcester
- Heather EliasWorcester$13K
- Nina RosanoWorcester$12K
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.